, Le jeûne induirait une diminution de l'inflammation articulaire, cependant il n'est pas recommandé du fait des risques qu'il comporte. Le régime méditerranéen (légumes, fruits, céréales, huile d'olive et poisson) semble améliorer la qualité de vie des patients avec un bénéfice cardiovasculaire démontré, cependant il n'a pas montré d'amélioration des paramètres biologiques, Les régimes végétariens et d'exclusion ne sont pas recommandés en raison du risque de carences qu'ils entraînent
, Il est donc important de prendre conseil auprès d'un spécialiste en cas de changement d'alimentation, afin d'éviter les carences alimentaires et les erreurs de régime
, En cas de surcharge pondérale, il est recommandé d'avoir une alimentation moins riche en calories
, La prise de corticoïdes entraîne également une modification du régime alimentaire : faible en sucre et en sel, apports en calcium alimentaire
, du fait des interactions qu'il peut engendrer avec les différents traitements. Le tabac est déconseillé
, Le pharmacien est aussi force de conseils hygiénodiététiques, p.179
Histoire de l'immunologie, Presses universitaires de France ,
Texte imprimé] : histoire de l'immunologie de Pasteur au SIDA. Paris : Presses universitaires de France, impr, Impr. des PUF, p.41, 1991. ,
1854-1915): man with the magic bullet, Singapore Med J, vol.51, issue.11, pp.842-845, 2010. ,
Ehrlich's Magic Bullets, N Engl J Med. 11 mars, vol.350, issue.11, pp.1079-80, 2004. ,
The contributions of Paul Ehrlich to infectious disease, J Infect. mars, vol.54, issue.3, pp.221-225, 2007. ,
From the structure of antibodies to the diversification of the immune response, Biosci Rep. oct, vol.24, issue.4-5, pp.280-301, 2004. ,
Cesar Milstein, the father of modern immunology, Nat Immunol, issue.6, p.501, 2002. ,
DOI : 10.1038/ni0602-501
From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal, Immunol Lett. sept, vol.161, issue.1, pp.96-105, 2014. ,
Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, beaucoup d'ingénierie, et ? quelques succès cliniques, Transfus Clin Biol. juin, vol.12, issue.2, pp.114-136, 2005. ,
DOI : 10.1016/j.tracli.2005.04.016
, Curr Biol CB. 30 avr, vol.12, issue.9, pp.308-318, 1927.
, ANSM : Agence nationale de sécurité du médicament et des produits de santé
,
,
, , 2007.
, Association des Collèges des Enseignants d'Immunologie. Immunologie fondamentale et immunopathologie
Fondements de l'immunologie, 2008. ,
Génétique des immunoglobulines ,
Bases immunologiques à la compréhension du concept d'anticorps monoclonal, Rev Médicale Liège. Mai, vol.64, issue.5-6, pp.237-280, 2009. ,
Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Médicale Liège, vol.64, issue.5-6, pp.244-251, 2009. ,
Les anticorps monoclonaux : apprenons à les connaître, Actual Pharm. nov, vol.52, issue.530, pp.18-22, 2013. ,
DOI : 10.1016/j.actpha.2013.09.005
,
, Rev Médicale Liège. 5 juin, vol.64, issue.5-6, pp.248-52, 2009.
est-ce qu'une biothérapie ? L'exemple des anticorps monoclonaux, Presse Médicale. mai, vol.38, issue.5, pp.825-856, 2009. ,
DOI : 10.1016/j.lpm.2008.12.025
Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques, C R Biol. avr, vol.329, issue.4, pp.217-244, 2006. ,
Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc Natl Acad Sci U S A. 1 févr, vol.91, issue.3, pp.969-73, 1994. ,
Human monoclonal antibodies by immortalization of memory B cells, Curr Opin Biotechnol. déc, vol.18, issue.6, pp.523-531, 2007. ,
Strategy for the production of human monoclonal antibodies using in vitro activated B cells, J Immunol Methods, vol.123, issue.2, pp.157-65, 1989. ,
Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature. 28 avr, vol.368, issue.6474, pp.856-865, 1994. ,
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat Genet. mai, vol.7, issue.1, pp.13-21, 1994. ,
Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and ? loci and expression of fully human antibodies, Proc Natl Acad Sci, vol.18, issue.2, p.722, 2000. ,
Phage display-derived human antibodies in clinical development and therapy. mAbs, vol.8, pp.1177-94, 2016. ,
Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display, Nat Biotechnol. déc, vol.18, issue.12, pp.1287-92, 2000. ,
Isolation of highaffinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses, J Immunol Methods. janv, vol.416, pp.49-58, 2015. ,
Antibodies to watch in 2017, mAbs. 17 févr, vol.9, issue.2, pp.167-81, 2017. ,
, Top 10 Best-selling Biologicals of 2015, 2016.
, Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR
, , 2017.
, Monoclonal Antibodies (mAbs) Market Size Worth $138.6 Billion By, p.2024
,
,
, Bientôt des anticorps monoclonaux (AcMo) pour toutes les maladies ? | LEEM-Les entreprises du médicament
, Monoclonal Antibodies (mAbs) Market Size | Industry Report, pp.2013-2024
, Les référentiels des collèges, 2015.
La polyarthrite rhumatoïde de l'adulte, 2003. ,
La polyarthrite rhumatoïde de l'adulte, Le Quotidien du médecin, 2004. ,
, Polyarthrite rhumatoïde | la rhumatologie pour tous
,
Chapitre 3-Polyarthrite rhumatoïde, Imagerie Musculosquelettique : Pathologies Générales, pp.97-136, 2013. ,
153-Polyarthrite rhumatoïde, Médecine interne de Netter, pp.1171-1177, 2011. ,
Mécanismes cellulaires de la réponse immune anti-FVIII chez les patients hémophiles A. Hématologie, vol.16, pp.372-81, 2010. ,
Épidémiologie et physiopathologie de la polyarthrite rhumatoïde, Actual Pharm. déc, vol.52, issue.531, pp.1-2, 2013. ,
Immunopathologie de la polyarthrite rhumatoïde, EMCRhumatol-Orthopédie. mai, vol.1, issue.3, pp.218-248, 2004. ,
Anti-TNF therapy in the injured spinal cord, Trends Pharmacol Sci. 1 févr, vol.32, issue.2, pp.107-122, 2011. ,
Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde, Rev Rhum. juill, vol.81, issue.4, pp.303-315, 2014. ,
Chapitre 12-Polyarthrite rhumatoïde, Orthèses De la Main et du Poignet Protocoles De Rééducation, pp.171-94, 2012. ,
18-Traitement de la polyarthrite rhumatoïde, Pharmacie clinique et thérapeutique (3e édition entièrement revue, pp.367-85, 2008. ,
, VIDAL-NOVATREX 2,5 mg cp
500 mg cp enr gastrorésis ,
,
10 mg cp pellic ,
,
200 mg cp pellic ,
,
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences, Biol Targets Ther. juin, vol.2, issue.2, pp.229-52, 2008. ,
50 mg sol inj en seringue préremplie ,
,
Interleukin-1 and acute brain injury. Front Cell Neurosci, vol.9, 2015. ,
DOI : 10.3389/fncel.2015.00018
URL : https://www.frontiersin.org/articles/10.3389/fncel.2015.00018/pdf
, , vol.67, 2017.
, /(type)/name/(value)/kineret/(cip)/3400927732034#nav-buttons
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther. 26 janv, vol.5, pp.61-70, 2011. ,
125 mg sol inj en stylo prérempli ,
,
, , 2009.
Inflammatory pathways of importance for management of inflammatory bowel disease, World J Gastroenterol, vol.20, issue.1, p.64, 2014. ,
, Remicade 100mg, poudre pour solution à diluer pour perfusion
, Humira 40mg, solution injectable en seringue préremplie
,
, Cimzia 200mg, solution injectable
, Simponi 100mg, solution injectable en seringue préremplie
,
Anticorps monoclonaux dans le traitement de la polyarthrite rhumatoïde : vers une révolution thérapeutique, C R Biol. avr, vol.329, issue.4, pp.228-268, 2006. ,
DOI : 10.1016/j.crvi.2005.12.008
Selected cytokine pathways in rheumatoid arthritis, Semin Immunopathol. 17 févr, pp.1-19, 2017. ,
100 mg pdre p sol diluer p perf ,
,
, /(type)/name/(value)/simponi/(cip)/3400927568480#nav-buttons
, /(type)/name/(value)/humira/(cip)/3400936223059#nav-buttons
, /(type)/name/(value)/cimzia/(cip)/3400939732008#nav-buttons
Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française, Rev Rhum, vol.80, issue.5, pp.459-66, 2013. ,
Biomarqueurs prédictifs de la réponse aux anti-TNF alpha dans la polyarthrite rhumatoïde. Rev Rhum, vol.77, pp.448-57, 2010. ,
32Maintien thérapeutique des anti TNF-alpha sous-cutanés dans la Polyarthrite Rhumatoïde, la Spondylarthrite Ankylosante et le Rhumatisme Psoriasique des patients naïfs de biothérapies en France, Rev Rhum, vol.83, 2016. ,
Taux de rétention de l'adalimumab, de l'étanercept et de l'infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante, Rev Rhum. déc, vol.81, issue.6, pp.483-90, 2014. ,
Lu-011-Maintenance thérapeutique des anti TNF au cours des Rhumatismes Inflammatoires Chronique, Rev Rhum, vol.83, pp.206-213, 2016. ,
Rôle de l'interleukine6 dans les destructions ostéoarticulaires et la perte osseuse systémique au cours de la polyarthrite rhumatoïde, Rev Rhum. mai, vol.77, issue.3, pp.233-241, 2010. ,
Tocilizumab-A novel therapy for non-organ-specific autoimmune diseases, Best Pract Res Clin Rheumatol. févr, vol.26, issue.1, pp.157-65, 2012. ,
, Roactemra 162 mg, solution injectable en seringue préremplie
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, Arch Pharm Res, vol.38, issue.5, pp.575-84, 2015. ,
, Roactemra 20mg/mL, solution à diluer pour perfusion
,
, /(type)/name/(value)/roactemra/(cip)/3400927824845#nav-buttons
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial, Clin Exp Rheumatol. août, vol.34, issue.4, pp.625-658, 2016. ,
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis, Clin Rheumatol. 1 févr, vol.36, issue.2, pp.241-50, 2017. ,
Lu-073Polyarthrite rhumatoïde et tocilizumab : Efficacité et tolérance lors du passage à la sous cutanée, Rev Rhum, vol.83, pp.237-245, 2016. ,
Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study, Rheumatol Ther. déc, vol.3, issue.2, p.291, 2016. ,
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules, Ann Rheum Dis, vol.71, issue.11, pp.1820-1826, 2012. ,
Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice, Reumatol Clin. 10 mai, 2016. ,
Le rituximab : une nouvelle possibilité thérapeutique dans la polyarthrite rhumatoïde. Rev Rhum, vol.75, pp.782-791, 2008. ,
B lymphocytes on the front line of autoimmunity, Autoimmun Rev, vol.5, pp.215-236, 2006. ,
, Mabthera 100mg, solution à diluer pour perfusion
,
Rituximab Treatment in Hepatitis C Infection: An In Vitro Model to Study the Impact of B Cell Depletion on Virus Infectivity, PLoS ONE, vol.6, issue.9, 2011. ,
Surveillance et précautions à prendre lors d'un traitement par un immunomodulateur biologique, Rev Médecine Interne. déc, vol.31, pp.315-323, 2010. ,
Lu-067-Analyse rétrospective de l'efficacité du rituximab dans le traitement de la polyarthrite rhumatoïde (PR) dans la vrai vie, Rev Rhum, vol.83, 2016. ,
Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab : évaluation ouverte de 175 patients, Rev Rhum. déc, vol.83, issue.6, pp.457-60, 2016. ,
Di035-Tolérance du rituximab au cours de la polyarthrite rhumatoïde dans la vraie vie, Rev Rhum, vol.83, pp.182-185, 2016. ,
CD6 as a Therapeutic Target in Autoimmune Diseases: Successes and Challenges, BioDrugs. 1 juin, vol.27, issue.3, pp.191-202, 2013. ,
Immunological evaluation of rheumatoid arthritis patients treated with itolizumab. mAbs, vol.8, pp.187-95, 2015. ,
Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis ,
, , 2015.
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab, Curr Drug Targets, vol.17, issue.6, pp.666-77, 2016. ,
Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study, Clin Rheumatol. 1 avr, vol.35, issue.4, pp.1059-64, 2016. ,
Emerging Therapies for Rheumatoid Arthritis, Rheumatol Ther. 3 juin, vol.3, issue.1, pp.31-42, 2016. ,
Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials, Rheumatol Int. août, vol.36, issue.8, pp.1065-75, 2016. ,
IL-17 as a future therapeutic target for rheumatoid arthritis, Nat Rev Rheumatol. oct, vol.5, issue.10, pp.549-53, 2009. ,
Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A, J Inflamm Res. 19 avr, vol.9, pp.39-50, 2016. ,
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis, J Rheumatol. 1 févr, vol.43, issue.2, pp.289-97, 2016. ,
, First Global Approval. Drugs. 1 févr, vol.75, issue.3, pp.329-367, 2015.
Secukinumab for rheumatology: development and its potential place in therapy, Drug Des Devel Ther. 24 juin, vol.10, pp.2069-80, 2016. ,
Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study, J Rheumatol. 1 mars, vol.43, issue.3, pp.495-503, 2016. ,
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis, Rheumatology. 1 janv, vol.55, issue.1, pp.49-55, 2016. ,
A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate, J Rheumatol. 1 juin, vol.42, issue.6, pp.912-921, 2015. ,
Brodalumab: First Global Approval, Drugs. sept, vol.76, issue.14, pp.1403-1415, 2016. ,
Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis ,
, Core Evidence, 2014.
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date, Drug Des Devel Ther. 13 janv, vol.11, pp.211-234, 2017. ,
Targeting GM-CSF in rheumatoid arthritis, Clin Exp Rheumatol. août, vol.34, issue.4, pp.39-44, 2016. ,
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis, Ann Rheum Dis. 16 févr, 2017. ,
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial, Ann Rheum Dis. juin, vol.74, issue.6, pp.1058-64, 2015. ,
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date, Drug Des Devel Ther. 26 sept, vol.10, pp.3083-98, 2016. ,
, Discovery and characterization of olokizumab. mAbs. 1 mai, vol.6, issue.3, pp.773-81, 2014.
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1607-1622, 2014. ,
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1595-1602, 2014. ,
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, Mod Rheumatol. 2 janv, vol.26, issue.1, pp.15-23, 2016. ,
Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis, Expert Opin Biol Ther, vol.16, issue.10, pp.1303-1312, 2016. ,
Sarilumab, a fully human monoclonal antibody against IL-6R? in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1626-1660, 2014. ,
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial, Arthritis Res Ther, vol.18, issue.1, 2016. ,
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study, Arthritis Rheumatol. 1 juin, vol.67, issue.6, pp.1424-1461, 2015. ,
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors, Arthritis Rheumatol. 1 févr, vol.69, issue.2, pp.277-90, 2017. ,
DOI : 10.1002/art.39944
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.39944
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial, Ann Rheum Dis, vol.16, 2016. ,
Antibodies to watch in 2017, mAbs. 17 févr, vol.9, issue.2, pp.167-81, 2017. ,
DOI : 10.1080/19420862.2016.1269580
URL : https://www.tandfonline.com/doi/pdf/10.1080/19420862.2016.1269580?needAccess=true
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach, J Clin Pharmacol. 1 déc, vol.55, issue.12, pp.1386-94, 2015. ,
Sirukumab, a human antiinterleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dosefinding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1616-1641, 2014. ,
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. The Lancet ,
,
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, DoseRanging Study, Arthritis Rheumatol, vol.67, issue.10, pp.2591-600, 2015. ,
, UPDATE: FDA rejects Sanofi's promising Rheumatoid Arthritis Drug
, , 2016.
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human AntiInterleukin-1? Monoclonal Antibody, Clin Pharmacokinet. juin, vol.51, issue.6, p.1, 2012. ,
,
,
,
Étude des polymorphismes des gènes de l'interleukine-1 et de l'antagoniste du récepteur de l'interleukine-1 chez des patients atteints de polyarthrite rhumatoïde, Pathol Biol. déc, vol.61, issue.6, pp.264-272, 2013. ,
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study, BMC Musculoskelet Disord, vol.12, p.153, 2011. ,
Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis, Rheumatol Int. 24 févr, 2017. ,
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, Arthritis Rheum. 1 févr, vol.64, issue.2, pp.360-70, 2012. ,
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebocontrolled, parallel-group phase III trial, Arthritis Rheum. 1 févr, vol.64, issue.2, pp.350-359, 2012. ,
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial, Ann Rheum Dis. 1 août, vol.71, issue.8, pp.1289-96, 2012. ,
Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program, PLOS ONE. févr, vol.9, issue.2, p.87379, 2014. ,
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial, Ann Rheum Dis. 1 déc, vol.70, issue.12, pp.2119-2144, 2011. ,
Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases, Immunotherapy. sept, vol.8, issue.9, pp.1091-1097, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01834266
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, Rheumatoid Arthritis: Results from Three Clinical Trials, vol.11, p.157961, 2016. ,
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, J Rheumatol. 1 juill, vol.40, issue.7, pp.1089-96, 2013. ,
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis, Arthritis Res Ther, vol.16, p.415, 2014. ,
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study, RMD Open. 1 août, vol.1, issue.1, p.37, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01901102
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study, Ann Rheum Dis. 1 août, vol.74, issue.8, pp.1567-70, 2015. ,
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus, Br J Clin Pharmacol. 1 mai, vol.81, issue.5, pp.908-925, 2016. ,
The role of BAFF in B-cell maturation, T-cell activation and autoimmunity, Trends Immunol. 1 mars, vol.23, issue.3, pp.113-118, 2002. ,
The impact of biological therapy on regulatory T cells in rheumatoid arthritis, Rheumatology. 1 mai, vol.54, issue.5, pp.768-75, 2015. ,
Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061), Immunol Cell Biol. avr, vol.93, issue.4, pp.321-323, 2015. ,
Tregalizumab-A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol, vol.25 ,
A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway, Immunol Cell Biol. avr, vol.93, issue.4, pp.396-405, 2015. ,
The novel regulatory T cell (Treg) agonistic monoclonal antibody (mAb) tregalizumab (BT-061): further characterization of mechanism of action, epitope binding, and clinical effects in patients with rheumatoid arthritis, Biotest-Nat Life, 2011. ,
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate, Ann Rheum Dis. 13 janv, 2017. ,
IL-23-IL-17 immune axis: Discovery, Mechanistic Understanding, and Clinical Testing, Nat Rev Immunol. sept, vol.14, issue.9, pp.585-600, 2014. ,
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nat Med. juill, vol.21, issue.7, pp.719-748, 2015. ,
L'accompagnement du patient atteint de polyarthrite rhumatoïde à l'officine, Actual Pharm. déc, vol.52, issue.531, pp.14-21, 2013. ,
Délivrance d'un anticorps monoclonal à l'officine. Actual Pharm, vol.52, pp.33-37, 2013. ,
, Cespharm-Comprendre la polyarthrite rhumatoïde-brochure
LD-La prise en charge de votre polyarthrite rhumatoïde ,
, Fiches traitements-Association Nationale de Défense contre l'Arthrite Rhumatoïde
, AFP-Site d'information sur la Polyarthrite Rhumatoïde et les Rhumatismes Inflammatoires Chroniques
, Parcours bon usage anti-TNF alpha-Maladies inflammatoires chroniques
Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française, Rev Rhum, vol.80, issue.5, pp.459-66, 2013. ,
, Club Rhumatismes et Inflammations-Fiches pratiques & RecommandationsTraitements anti-TNFa et suivi de tolérance
, Idées reçues ou autres questions ? | la rhumatologie pour tous, 2016.
Activité physique et polyarthrite rhumatoïde, Rev Rhum. mars, vol.83, issue.2, pp.99-104, 2016. ,
56A-Régimes diététiques et polyarthrite rhumatoïde : Revue systématique de la littérature, Rev Rhum. nov, vol.83, pp.73-77, 2016. ,
Les effets des régimes et des stratégies diététiques dans la polyarthrite rhumatoïde. Rev Rhum, vol.82, pp.283-90, 2015. ,